Member Info for ratcliffewriter

Well said. It certainly puts lofas into a new perspective too.

Thanks Bermuda - Dr Peston will just have to talk quickly then!

Good to see the presentation is a 90 minute slot - maybe some more results to come ahead of it perhaps?

Does the RNS mean Thursday 16th or is it on Friday 17th?

Seems some larger buyers were unconvinced by lofa and Dracula's compelling arguments then.

WTP - the 'astute' only ever comment on sells, it's part of being balanced. 'We can all agree' on that.

I like the way the BBC website article has the quote 'you couldn't give this to the next patient in the line because you wouldn't expect it to work.

"It's truly personalised."'

Makes it.sound like an advantage rather than a drawback. If Scancell vaccines come along as hoped, imagine the quotes available for them - ' off the shelf', 'universal' etc.

Just have to wait and see.

I think even you known the answer to that Dracula.

You'll have to try a lot harder to bridge your credibility gap.

True, but it's nice to have some goals in life I suppose.

Oh, my apologies, I missed 'Glee Club' as well. Comedy gold blasts from the past.

'Astute.'

Wonderful.

Predictably tiresome to see who pops up with what and when. Also faintly amusing, to be honest, but definitely predictable and tiresome. AB124 will probably be along in a bit too.

Indeed Bob - SCLP is going to be bought out for a pittance the instant Redmile go over 30 percent (obviously imminent several months ago), then they're going to delist, then there's no interest from anyone for anything, but meanwhile recruitment to the trials progresses well, and a target ORR of 70 percent (ambitiously beyond the industry standard) is comfortably exceeded. Some people seem to forget how rigorous and thorough trials are, and how the issuing of updates every two minutes would probably be a bad sign. Prolonged silence means work is progressing imo. Patience is a virtue, but the exit door is always available to those who want out.

I imagine the main reason for delisting being brought up is because finances are steady, and trials are properly established and looking favourable. While anything is a possibility, delisting wasn't mentioned even during the financially very tight times and a trial drought. There will be a few who probably wish they'd thought of stirring the pot with this new bête noir to assist with a bit of trading leverage.

Imo if they were really constrained to presenting 'old' data, they wouldn't bother going unless there were newer data ready or imminent. Scancell have never wasted money going to events like AACR just for the shoulder-rubbing. This time, unlike previous events, they are physically presenting as well, not just doing a poster. Even if there is no RNS tomorrow, I am confident that more good results are coming. After all, would you present at AACR knowing that your next update was retrograde or disappointing?

Nothing fishy I presume - just the scale of it. Scancell is a minnow, but not for much longer I trust.

I'm not a scientist, but I think I'd be pretty chuffed to stand up at AACR and present that sort of stuff. What do you reckon crackin?

Results 19 patients received the combination of SCIB1 with nivolumab and ipilimumab. At study entry, all patients were stage IV. 13 patients had reached the first imaging timepoint at 13 weeks, and the objective response rate is 85%. 9/9 responses were confirmed in a subsequent scan. Patients showed a 40-95% reduction in tumor volume between 13 and 25 weeks. Most of the SCIB1-related adverse events were Grade 1/2. Only 1 patient reported a Grade 3 rash. No enhancement of immune-mediated adverse events was observed when SCIB1 was added to nivolumab with ipilimumab.

Conclusions SCIB1 in combination with nivolumab and ipilimumab as first line treatment for unresectable melanoma improved the ORR to 85% without an increase in clinically meaningful adverse events. These results if confirmed in a larger patient cohort provide confidence in initiating a randomized registration program in unresectable melanoma patients with the novel DNA plasmid technology

Cobaltblue - 'adam' (or whoever he is) is still registered on LSE as rhubarbmk2 but has only posted twice since last summer on a different share. His last VAL post was going on about lack of institutional investors, but that's not new to VAL....

They'll either update on presentation or at some point after,. I'm really not bothered if that takes minutes, days or weeks as things stand. It looks promising and it will come when it comes.

Having no clinical trials doesn't seem to be pulling in the crowds either.